Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Circumcision, Male | 9 | 2024 | 99 | 3.050 |
Why?
|
| Tuberculosis | 21 | 2025 | 543 | 2.700 |
Why?
|
| Chronic Disease | 5 | 2020 | 107 | 2.560 |
Why?
|
| HIV Infections | 34 | 2024 | 5097 | 1.910 |
Why?
|
| South Africa | 69 | 2025 | 7596 | 1.860 |
Why?
|
| Humans | 78 | 2025 | 14537 | 1.620 |
Why?
|
| Tuberculosis, Pulmonary | 9 | 2023 | 324 | 1.570 |
Why?
|
| Ambulatory Care Facilities | 6 | 2022 | 125 | 1.440 |
Why?
|
| Male | 46 | 2024 | 6754 | 1.430 |
Why?
|
| Disease Management | 3 | 2020 | 74 | 1.380 |
Why?
|
| Adult | 44 | 2024 | 5913 | 1.340 |
Why?
|
| Funeral Homes | 2 | 2019 | 6 | 1.200 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2023 | 256 | 1.180 |
Why?
|
| Contact Tracing | 7 | 2023 | 48 | 1.170 |
Why?
|
| Cross-Sectional Studies | 21 | 2023 | 1422 | 1.130 |
Why?
|
| Mycobacterium tuberculosis | 7 | 2023 | 329 | 1.040 |
Why?
|
| Mass Screening | 6 | 2023 | 245 | 0.980 |
Why?
|
| Pre-Exposure Prophylaxis | 6 | 2024 | 196 | 0.940 |
Why?
|
| Communicable Disease Control | 4 | 2023 | 101 | 0.860 |
Why?
|
| Female | 32 | 2024 | 9103 | 0.800 |
Why?
|
| Young Adult | 19 | 2024 | 2498 | 0.800 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 33 | 0.780 |
Why?
|
| Latent Tuberculosis | 3 | 2020 | 45 | 0.750 |
Why?
|
| Surgical Instruments | 3 | 2019 | 11 | 0.740 |
Why?
|
| Penis | 2 | 2019 | 8 | 0.730 |
Why?
|
| Disease Notification | 2 | 2025 | 14 | 0.720 |
Why?
|
| Organizational Culture | 1 | 2020 | 7 | 0.660 |
Why?
|
| Middle Aged | 20 | 2024 | 3601 | 0.650 |
Why?
|
| Models, Economic | 1 | 2020 | 15 | 0.650 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 42 | 0.640 |
Why?
|
| Prospective Studies | 14 | 2024 | 1160 | 0.640 |
Why?
|
| Health Personnel | 4 | 2019 | 231 | 0.620 |
Why?
|
| Antitubercular Agents | 3 | 2021 | 322 | 0.620 |
Why?
|
| Medical Waste Disposal | 1 | 2019 | 3 | 0.610 |
Why?
|
| Safety Management | 1 | 2019 | 4 | 0.610 |
Why?
|
| Amputation, Traumatic | 1 | 2019 | 2 | 0.610 |
Why?
|
| Child | 15 | 2024 | 2242 | 0.610 |
Why?
|
| Personal Protective Equipment | 1 | 2019 | 16 | 0.610 |
Why?
|
| Adolescent | 16 | 2024 | 2985 | 0.610 |
Why?
|
| Self Care | 1 | 2019 | 14 | 0.610 |
Why?
|
| Postoperative Complications | 1 | 2019 | 34 | 0.610 |
Why?
|
| Serologic Tests | 1 | 2019 | 26 | 0.600 |
Why?
|
| Health Care Costs | 2 | 2019 | 115 | 0.600 |
Why?
|
| Pain | 2 | 2018 | 41 | 0.600 |
Why?
|
| Mortuary Practice | 1 | 2019 | 3 | 0.590 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 1324 | 0.580 |
Why?
|
| Occupational Diseases | 1 | 2019 | 40 | 0.570 |
Why?
|
| Research | 1 | 2019 | 65 | 0.570 |
Why?
|
| Isoniazid | 2 | 2020 | 110 | 0.560 |
Why?
|
| Influenza, Human | 4 | 2023 | 374 | 0.530 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 239 | 0.520 |
Why?
|
| Treatment Refusal | 1 | 2016 | 13 | 0.490 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2021 | 195 | 0.480 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 200 | 0.480 |
Why?
|
| HIV Seropositivity | 3 | 2023 | 265 | 0.480 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2023 | 262 | 0.460 |
Why?
|
| Inservice Training | 1 | 2015 | 7 | 0.460 |
Why?
|
| Allied Health Personnel | 1 | 2015 | 6 | 0.460 |
Why?
|
| Politics | 1 | 2015 | 24 | 0.450 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 132 | 0.440 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 54 | 0.440 |
Why?
|
| Rural Health Services | 1 | 2015 | 48 | 0.440 |
Why?
|
| HIV | 6 | 2023 | 380 | 0.420 |
Why?
|
| Primary Health Care | 5 | 2023 | 240 | 0.400 |
Why?
|
| Sputum | 4 | 2023 | 135 | 0.400 |
Why?
|
| Floxacillin | 1 | 2013 | 6 | 0.390 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 13 | 0.390 |
Why?
|
| Foreskin | 3 | 2024 | 12 | 0.390 |
Why?
|
| Epidemics | 2 | 2024 | 65 | 0.390 |
Why?
|
| Child, Preschool | 7 | 2024 | 1748 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 293 | 0.330 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2024 | 155 | 0.330 |
Why?
|
| Models, Organizational | 2 | 2020 | 3 | 0.320 |
Why?
|
| Prevalence | 7 | 2023 | 1192 | 0.310 |
Why?
|
| Health Expenditures | 2 | 2019 | 39 | 0.290 |
Why?
|
| Aged | 7 | 2023 | 1740 | 0.290 |
Why?
|
| Infant | 6 | 2024 | 2244 | 0.250 |
Why?
|
| Emtricitabine | 2 | 2023 | 78 | 0.230 |
Why?
|
| Incidence | 5 | 2024 | 685 | 0.230 |
Why?
|
| Tuberculin Test | 4 | 2020 | 49 | 0.230 |
Why?
|
| Smoking Cessation | 1 | 2024 | 9 | 0.220 |
Why?
|
| Tight Junctions | 1 | 2024 | 2 | 0.220 |
Why?
|
| Rural Population | 4 | 2021 | 654 | 0.220 |
Why?
|
| Cohort Studies | 6 | 2024 | 967 | 0.220 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 60 | 0.220 |
Why?
|
| Treatment Outcome | 4 | 2024 | 889 | 0.210 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 101 | 0.210 |
Why?
|
| Sexual Health | 1 | 2023 | 14 | 0.200 |
Why?
|
| Intention | 1 | 2023 | 23 | 0.200 |
Why?
|
| Nicotine | 1 | 2023 | 12 | 0.200 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2024 | 656 | 0.190 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 7 | 0.190 |
Why?
|
| Cannabis | 1 | 2022 | 10 | 0.190 |
Why?
|
| Tobacco Smoking | 2 | 2022 | 15 | 0.190 |
Why?
|
| Motivation | 1 | 2023 | 59 | 0.190 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 29 | 0.190 |
Why?
|
| Whooping Cough | 1 | 2023 | 36 | 0.190 |
Why?
|
| Chemokine CCL4 | 1 | 2022 | 14 | 0.190 |
Why?
|
| Family Characteristics | 5 | 2022 | 135 | 0.180 |
Why?
|
| Risk Factors | 6 | 2022 | 1475 | 0.180 |
Why?
|
| Bacterial Load | 1 | 2021 | 32 | 0.170 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 34 | 0.170 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.170 |
Why?
|
| Telemedicine | 1 | 2021 | 25 | 0.170 |
Why?
|
| HIV-1 | 3 | 2024 | 1260 | 0.170 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 21 | 0.170 |
Why?
|
| Rural Health | 1 | 2021 | 118 | 0.170 |
Why?
|
| Cell Phone | 1 | 2020 | 34 | 0.160 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 103 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2019 | 30 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 299 | 0.150 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 7 | 0.150 |
Why?
|
| Waste Disposal Facilities | 1 | 2019 | 9 | 0.150 |
Why?
|
| Workload | 1 | 2019 | 13 | 0.150 |
Why?
|
| Tobacco Use | 1 | 2019 | 12 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 39 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 26 | 0.150 |
Why?
|
| Program Development | 1 | 2019 | 32 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2019 | 101 | 0.150 |
Why?
|
| Research Personnel | 1 | 2019 | 19 | 0.150 |
Why?
|
| Coinfection | 2 | 2020 | 276 | 0.140 |
Why?
|
| Virus Shedding | 1 | 2018 | 24 | 0.140 |
Why?
|
| Poverty | 1 | 2019 | 152 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2020 | 151 | 0.140 |
Why?
|
| Orthomyxoviridae | 1 | 2018 | 33 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2020 | 1479 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 8 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 188 | 0.140 |
Why?
|
| Analgesia | 1 | 2018 | 8 | 0.140 |
Why?
|
| Pain Management | 1 | 2018 | 12 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2019 | 167 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2018 | 56 | 0.140 |
Why?
|
| Seroepidemiologic Studies | 3 | 2023 | 109 | 0.140 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2017 | 5 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 563 | 0.140 |
Why?
|
| Sex Workers | 1 | 2019 | 116 | 0.140 |
Why?
|
| Air Pollution, Indoor | 1 | 2017 | 13 | 0.130 |
Why?
|
| Vaccination | 1 | 2019 | 365 | 0.130 |
Why?
|
| Pleural Cavity | 1 | 2017 | 7 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 106 | 0.130 |
Why?
|
| Radiography | 1 | 2017 | 80 | 0.130 |
Why?
|
| Genital Diseases, Male | 1 | 2016 | 8 | 0.120 |
Why?
|
| Perception | 1 | 2016 | 42 | 0.120 |
Why?
|
| Pain Measurement | 1 | 2015 | 15 | 0.120 |
Why?
|
| Lung | 1 | 2015 | 70 | 0.110 |
Why?
|
| Quality Control | 1 | 2015 | 27 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 14 | 0.110 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 13 | 0.110 |
Why?
|
| Schools | 1 | 2015 | 73 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2019 | 799 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 217 | 0.110 |
Why?
|
| Product Packaging | 1 | 2014 | 2 | 0.110 |
Why?
|
| Crime | 1 | 2014 | 3 | 0.110 |
Why?
|
| Tobacco Products | 1 | 2014 | 8 | 0.110 |
Why?
|
| Commerce | 1 | 2014 | 22 | 0.110 |
Why?
|
| Time Factors | 1 | 2015 | 507 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2013 | 127 | 0.100 |
Why?
|
| Uganda | 2 | 2024 | 197 | 0.090 |
Why?
|
| Seasons | 2 | 2023 | 154 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 253 | 0.090 |
Why?
|
| Viral Load | 3 | 2020 | 819 | 0.090 |
Why?
|
| Linear Models | 2 | 2023 | 83 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.090 |
Why?
|
| Autopsy | 2 | 2023 | 140 | 0.080 |
Why?
|
| Cotinine | 1 | 2024 | 7 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2025 | 55 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 48 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2024 | 64 | 0.050 |
Why?
|
| Phylogeny | 1 | 2024 | 231 | 0.050 |
Why?
|
| Counseling | 1 | 2024 | 143 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2023 | 12 | 0.050 |
Why?
|
| Cough | 1 | 2023 | 14 | 0.050 |
Why?
|
| Tenofovir | 1 | 2024 | 171 | 0.050 |
Why?
|
| Claudin-1 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2024 | 175 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 103 | 0.050 |
Why?
|
| Mutation | 1 | 2024 | 306 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2022 | 2 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 2 | 0.050 |
Why?
|
| Ion Channels | 1 | 2022 | 3 | 0.050 |
Why?
|
| Bordetella pertussis | 1 | 2023 | 29 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Chemokine CCL3 | 1 | 2022 | 23 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 52 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 435 | 0.050 |
Why?
|
| Smoking | 1 | 2023 | 100 | 0.050 |
Why?
|
| Carrier State | 1 | 2023 | 92 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2023 | 151 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 46 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 385 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 82 | 0.040 |
Why?
|
| Microscopy | 1 | 2021 | 21 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 303 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 35 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 47 | 0.040 |
Why?
|
| Obesity | 1 | 2024 | 367 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 59 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2020 | 120 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 336 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 370 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 278 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 47 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2021 | 215 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 244 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 30 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 87 | 0.040 |
Why?
|
| Income | 1 | 2019 | 85 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2019 | 65 | 0.040 |
Why?
|
| Urban Population | 1 | 2021 | 257 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 114 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 89 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 3 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 23 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 2018 | 49 | 0.030 |
Why?
|
| Kerosene | 1 | 2017 | 4 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 468 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 188 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 411 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 7 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2018 | 203 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2017 | 45 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2017 | 47 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 154 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 321 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2015 | 3 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2015 | 3 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 472 | 0.030 |
Why?
|
| Cities | 1 | 2014 | 37 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 179 | 0.030 |
Why?
|